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In the present issue of Critical Care, Pettila and colleagues 
report the ﬁ   rst single-centred pilot randomized 
controlled trial of activated protein C (APC) in alcohol-
induced acute pancreatitis of moderate severity but 
without infection [1]. After screening 215 patients, 32 
patients satisﬁ   ed the trial inclusion criteria and were 
randomized to either placebo or APC at 24 μg/kg/hour 
for 96 hours, in addition to standard therapy for acute 
pancreatitis. Th   e study – powered to evaluate the eﬀ  ect 
of APC on the change in organ dysfunction, measured 
using the Sequential Organ Failure Assessment score as 
the primary outcome – failed to show any beneﬁ  t.
In acute pancreatitis, severity is deﬁ  ned by the occur-
rence of organ failure and/or peri-pancreatic complica-
tions. Severe acute pancreatitis (SAP) is characterized by 
the presence of an overwhelming inﬂ  ammatory response, 
with unregulated activation of the coagulation system. 
Evaluation of the coagulation and the endogenous 
protein C/antithrombin III (AT III) system shows that 
nonsurvivors in SAP have signiﬁ   cantly lower levels of 
protein C and AT III activity, and higher levels of 
D-dimer and plasminogen activator inhibitor-1, than sur-
vivors [2]. Th  ese changes mirror the patterns seen in 
severe bacterial sepsis that suggest exhaustion of ﬁ  brino-
lysis and coagulation inhibitors, thereby identifying a 
possible role for APC in SAP independent of the need to 
diagnose severe sepsis. Prior to the study by Pettila and 
colleagues [1], the literature was limited to animal studies 
[3,4] and to subgroup data from the PROWESS trial of 62 
patients with acute pancreatitis and severe sepsis, where 
there was a trend to reduced mortality in those treated 
with APC (24% vs. 15%) [5]. Th  e Consensus Guidelines 
thus recom  mended that careful consideration is given to 
APC therapy in those patients with SAP and infection, 
given the theoretical but unproven concern of 
retroperitoneal haemorrhage [5].
SAP is a devastating disease with an attributable mor-
tality of around 30%, and thus interventional trials are 
required to ﬁ  nd a potential therapy to improve outcome. 
Although commendable, this pilot trial of APC in 
pancreatitis must be interpreted with caution. As the 
authors point out, the study is underpowered to detect 
any meaningful diﬀ   erence in the primary outcome – 
change in the Sequential Organ Failure Assessment score – 
as a surrogate for APC eﬀ  ect. Th   e authors also report no 
diﬀ  erence in bleeding complications, yet serious bleeding 
is actually a relatively infrequent event in patients treated 
with APC. In a meta-analysis of 10,679 APC-treated 
patients, the incidence of serious bleeding was 3.3% [6]. 
Th   is equates to approximately one serious bleeding event 
per 30 patients; consequently, in a study involving only 16 
APC-treated patients it is diﬃ   cult to draw any clinically 
relevant conclusions (good or bad) with respect to bleeding.
Th  e mortality beneﬁ   t with APC is best shown in 
patients with severe sepsis and high risk of death; for 
example, patients with multiple organ dysfunction, patients 
with Acute Physiology and Chronic Health Evaluation 
(APACHE) II score ≥25, or those in shock [7]. Th  ere  has 
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Severe acute pancreatitis (SAP) is characterized by 
an unregulated systemic proinfl  ammatory response 
secondary to activation of trypsin within the 
pancreatic tissue, resulting in multiple organ failure. 
This dysregulated infl  ammation leading to organ 
dysfunction also characterizes severe sepsis. Activated 
protein C (APC) has pleotropic eff  ects on the immune, 
coagulation, infl  ammatory and apoptotic pathways, 
and has been postulated to benefi  t acute pancreatitis – 
although concerns of possible retroperitoneal bleeding 
remain. Currently, experimental studies and subgroup 
data on patients with pancreatitis from a randomized 
controlled trial of APC in severe sepsis form the 
literature on the possible role of APC in SAP. We review 
the fi  rst randomized controlled trial of APC in acute 
pancreatitis published in the present issue of Critical 
Care.
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low risk of death, such as those in the lowest quartile of 
the PROWESS trial (that is, APACHE II score <17). Th  e 
severity of illness and risk of death due to acute 
pancreatitis in this pilot trial was low (mean age of 47, 
mean APACHE II score of 14 and zero mortality in the 
control arm). Moreover, 34% of the patients never 
required invasive ventilation and 37% never developed 
shock requiring a vasopressor. Th   e population studied is 
thus likely to be confounding the results. Indeed, for 
subsequent trials with APC the inclusion criteria have all 
focused on ensuring high severity of illness, including the 
important ongoing PROWESS-SHOCK trial [8,9].
Identifying individual patients who are likely to beneﬁ  t 
the most and to suﬀ   er the least morbidity from an 
intervention is a challenge, and there is an increasing role 
for biomarkers to assist in this endeavour. In the context 
of APC, serial measurements of protein C may be the 
best biomarker in establishing those most at risk of poor 
outcome in severe sepsis, may highlight those patients 
most likely to beneﬁ  t from APC, and also may prove 
useful in monitoring therapy [10]. As protein C deﬁ  ciency 
has been demonstrated in experimental early SAP, this 
trial might have been more relevant had it measured 
protein C as a biomarker. In addition, the observed low 
mortality in the study highlights the importance in study 
design of selecting a population who are genuinely at 
high risk of death and are potential ideal candidates for 
what is an expensive and debated therapy [2,11].
Th   is pilot study is underpowered to contribute signiﬁ  -
cantly to the baseline data necessary to inform the design 
of a future interventional trial assessing APC as a 
potential therapy in SAP. If further trials with APC are 
undertaken in this disease, it is essential they have the 
scope and ability to capture a genuinely high-risk popu-
lation and provide the intervention in a timely manner. 
Consideration should be given to selecting patients at 
highest risk of progressive organ dysfunction deﬁ  ned by 
at least moderate protein C deﬁ  ciency.
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